High Triglycerides Breakthrough Therapy: Icosapent Ethyl

March 8, 2021 University of Best Practices

  • Agenda|Bios|Video|PDF Invitation
  • Introduction to Residual Risk Topics and Talks (Presentation|Video)
    • William J. Bommer, MD, FACP, FACC – Statewide Chairman, Right Care Initiative University of Best Practices; Specialty Delegate, California American College of Cardiology and California Medical Association; Director, California ePCI Program; Director, Prevention Forward Program and Professor of Medicine, Division of Cardiovascular Medicine, University of California, Davis
  • The REDUCE-IT Trial (Presentation|Video)
    • Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC– Executive Director of Interventional Cardiovascular Programs; Professor, Harvard Medical School; Principal Investigator, REDUCE-IT Trial
  • Eligibility and Preventable Cardiovascular Events in US Population (Presentation|Video)
    • Nathan Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC – Professor, School of Medicine & Department of Epidemiology; Director, UCI Heart Disease Prevention Program, School of Medicine; University of California, Irvine
  • Cost-Effectiveness of Icosapent Ethyl (Presentation|Video)
    • William J. Bommer, MD, FACP, FACC – Statewide Chairman, Right Care Initiative University of Best Practices; Specialty Delegate, California American College of Cardiology and California Medical Association; Director, California ePCI Program; Director, Prevention Forward Program and Professor of Medicine, Division of Cardiovascular Medicine, University of California, Davis